Greek researchers have made breakthroughs in the development of small-cell lung cancer, aiming to eradicate the disease globally.
For that purpose, the study was presented at one of the renowned clinical studies on lung cancer at the American Society of Clinical Oncology (ASCO).
The masterpiece got published in the prestigious New England Journal of Medicine.
It was a major advancement in this virulent form of disease that accounts for 15-20% of lung cancer diagnosis in Greece and all across the globe.
However, the clinical results focus on a new class of biotechnology developed drug known as “T-cell engager”, which will play a pivotal role in strengthening the immune system. The desired results declared that 40% reduction occurs in the relative risk of death from this deadly disease.
Most importantly, the new treatment demonstrated that it retains better tolerance than traditional chemotherapy. It reduces the symptoms of breath, coughing and chest pain.
The novel immunotherapy approach has received massive appreciation and got approval in several countries including the United States, Japan, Brazil, Canada, UK and approval in Europe and Greece to be expected by 2026.
Dr Mountzios said, “Greece played a leading role in this significant scientific milestone.”
He further explained, “Our international recognition clearly demonstrates the capabilities of Greek research centers, which stand on par with the best global institutions in terms of infrastructure, and access to cutting-edge treatments. This marks a defining moment for Greece Oncology.”
This approach may play a crucial role in dealing with other tumors apart from lung cancer, where immune system and metabolic reprogramming are major barriers to its treatment.
With more clinical trials, it could evolve into a flexible platform for combination therapies, pushing current limitations in cancer care and making a new era of immune restoration.